BRIACELL THERAPEUTICS CORP. Fair Value Adjustment of Warrants
BRIACELL THERAPEUTICS CORP. (BCTX) reported Fair Value Adjustment of Warrants of -$123.24 thousand for the 3-month period ending 2026-04-30, per its 10-Q filed 2026-06-09.
Financial Statements › Cash Flow
us-gaap:FairValueAdjustmentOfWarrants · last filed 2026-06-09
- BRIACELL THERAPEUTICS CORP. fair value adjustment of warrants for the quarter ending 2026-04-30 was -$123.24K.
- BRIACELL THERAPEUTICS CORP. fair value adjustment of warrants for the quarter ending 2026-01-31 was -$211.78K.
- BRIACELL THERAPEUTICS CORP. fair value adjustment of warrants for the quarter ending 2025-10-31 was $69.20K, a 88.78% decline year-over-year.
- BRIACELL THERAPEUTICS CORP. fair value adjustment of warrants for the quarter ending 2025-07-31 was -$392.34K.
- BRIACELL THERAPEUTICS CORP. fair value adjustment of warrants for fiscal 2025 was -$758.36K.
- BRIACELL THERAPEUTICS CORP. fair value adjustment of warrants for fiscal 2024 was -$28.24M.
- BRIACELL THERAPEUTICS CORP. fair value adjustment of warrants for fiscal 2023 was -$2.12M, a 118.18% decline from fiscal 2022.
- BRIACELL THERAPEUTICS CORP. fair value adjustment of warrants for fiscal 2022 was $11.66M, a 162.05% increase from fiscal 2021.
| Period end | Fair Value Adjustment of Warrants 3 month | Fair Value Adjustment of Warrants 6 month | Fair Value Adjustment of Warrants 9 month | Fair Value Adjustment of Warrants 12 month |
|---|---|---|---|---|
| 2026-04-30 | -$123.24K 10-Q · filed 2026-06-09 | -$335.02K derived: sum of 2 quarters · filed 2026-06-09 | -$265.82K 10-Q · filed 2026-06-09 | -$658.16K derived: sum of 4 quarters · filed 2026-06-09 |
| 2026-01-31 | -$211.78K 10-Q · filed 2026-03-10 | -$142.58K 10-Q · filed 2026-03-10 | -$534.92K derived: sum of 3 quarters · filed 2026-03-10 | -$710.74K derived: sum of 4 quarters · filed 2026-06-09 |
| 2025-10-31 | $69.20K 10-Q · filed 2025-12-11 | -$323.14K derived: sum of 2 quarters · filed 2025-12-11 | -$498.96K derived: sum of 3 quarters · filed 2026-06-09 | -$1.31M derived: sum of 4 quarters · filed 2026-06-09 |
| 2025-07-31 | -$392.34K derived: 10-K 12 month − 10-Q 9 month · filed 2025-10-16 | -$568.17K derived: sum of 2 quarters · filed 2026-06-09 | -$1.38M derived: sum of 3 quarters · filed 2026-06-09 | -$758.36K 10-K · filed 2025-10-16 |
| 2025-04-30 | -$175.83K 10-Q · filed 2026-06-09 | -$982.67K derived: sum of 2 quarters · filed 2026-06-09 | -$366.02K 10-Q · filed 2026-06-09 | -$4.95M derived: sum of 4 quarters · filed 2026-06-09 |
| 2025-01-31 | -$806.84K 10-Q · filed 2026-03-10 | -$190.20K 10-Q · filed 2026-03-10 | -$4.77M derived: sum of 3 quarters · filed 2026-03-10 | -$15.72M derived: sum of 4 quarters · filed 2026-03-10 |
| 2024-10-31 | $616.64K 10-Q · filed 2025-12-11 | -$3.97M derived: sum of 2 quarters · filed 2025-12-11 | -$14.91M derived: sum of 3 quarters · filed 2025-12-11 | -$13.34M derived: sum of 4 quarters · filed 2025-12-11 |
| 2024-07-31 | -$4.58M derived: 10-K 12 month − 10-Q 9 month · filed 2025-10-16 | -$15.53M derived: sum of 2 quarters · filed 2025-10-16 | -$13.96M derived: sum of 3 quarters · filed 2025-10-16 | -$28.24M 10-K · filed 2025-10-16 |
| 2024-04-30 | -$10.95M 10-Q · filed 2025-06-16 | -$9.38M derived: sum of 2 quarters · filed 2025-06-16 | -$23.66M 10-Q · filed 2025-06-16 | -$28.75M derived: sum of 4 quarters · filed 2025-06-16 |
| 2024-01-31 | $1.57M 10-Q · filed 2025-03-12 | -$12.71M 10-Q · filed 2025-03-12 | -$17.81M derived: sum of 3 quarters · filed 2025-03-12 | -$18.35M derived: sum of 4 quarters · filed 2025-03-12 |
| 2023-10-31 | -$14.28M 10-Q · filed 2024-12-16 | -$19.37M derived: sum of 2 quarters · filed 2024-12-16 | -$19.91M derived: sum of 3 quarters · filed 2024-12-16 | -$12.28M derived: sum of 4 quarters · filed 2024-12-16 |
| 2023-07-31 | -$5.09M derived: 10-K 12 month − 10-Q 9 month · filed 2024-10-29 | -$5.63M derived: sum of 2 quarters · filed 2024-10-29 | $2.00M derived: sum of 3 quarters · filed 2024-10-29 | -$2.12M 10-K · filed 2024-10-29 |
| 2023-04-30 | -$539.43K 10-Q · filed 2024-06-14 | $7.09M derived: sum of 2 quarters · filed 2024-06-14 | $2.97M 10-Q · filed 2024-06-14 | -$1.75M derived: sum of 4 quarters · filed 2024-06-14 |
| 2023-01-31 | $7.63M 10-Q · filed 2024-03-18 | $3.51M 10-Q · filed 2024-03-18 | -$1.21M derived: sum of 3 quarters · filed 2024-03-18 | $4.71M derived: sum of 4 quarters · filed 2024-03-18 |
| 2022-10-31 | -$4.12M 10-Q · filed 2023-12-14 | -$8.84M derived: sum of 2 quarters · filed 2023-12-14 | -$2.92M derived: sum of 3 quarters · filed 2023-12-14 | -$17.71M derived: sum of 4 quarters · filed 2023-12-14 |
| 2022-07-31 | -$4.73M derived: 10-K 12 month − 10-Q 9 month · filed 2023-10-25 | $1.20M derived: sum of 2 quarters · filed 2023-10-25 | -$13.60M derived: sum of 3 quarters · filed 2023-10-25 | $11.66M 10-K · filed 2023-10-25 |
| 2022-04-30 | $5.93M 10-Q · filed 2023-06-14 | -$8.87M derived: sum of 2 quarters · filed 2023-06-14 | $16.38M 10-Q · filed 2023-06-14 | |
| 2022-01-31 | -$14.80M 10-Q · filed 2023-03-16 | $10.46M 10-Q · filed 2023-03-16 | ||
| 2021-10-31 | $25.25M 10-Q · filed 2022-12-14 | |||
| 2021-07-31 | $4.45M 10-K · filed 2022-10-28 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| PMGC Holdings Inc. (ELAB) | United States | $0.037B | |
| Seres Therapeutics, Inc. (MCRB) | United States | $0.036B | -3.45 |
| FILANA THERAPEUTICS, INC. (FLNA) | United States | $0.038B | -1.05 |
| Actinium Pharmaceuticals, Inc. (ATNM) | United States | $0.038B | 2.73 |
| MIRA PHARMACEUTICALS, INC. (MIRA) | United States | $0.036B | -4.30 |
| Celularity Inc (CELU) | United States | $0.038B | -0.34 |
| CervoMed Inc. (CRVO) | United States | $0.038B | -1.39 |
| Edesa Biotech, Inc. (EDSA) | Canada | $0.039B | |
| ROCKWELL MEDICAL, INC. (RMTI) | United States | $0.035B | |
| Karyopharm Therapeutics Inc. (KPTI) | United States | $0.039B | -0.98 |